to help him get through opioid withdrawal

LUCEMYRA is the first and only FDA-approved, non-opioid, non-addictive treatment for relief of multiple symptoms of opioid withdrawal to facilitate abrupt opioid discontinuation in adults.1 Learn more

Opioid Withdrawal Syndrome (OWS) makes opioid discontinuation difficult and extremely unpleasant

Avoidance of withdrawal is a powerful driver for continuing opioid use2

Primary reason for continuing opioid use among patients with chronic pain
  • According to a survey of patients with chronic pain, patients who initially took opioids for pain were more likely to continue taking opioids to avoid physical withdrawal (57%), rather than for pain relief (23%), or wanting to “get high” (14%)2

Symptoms of opioid withdrawal, sometimes known as OWS, are associated with both psychological distress and physical discomfort3

  • Signs and symptoms of OWS often present concurrently, ranging from actual physical pain, to emotional and sleep disturbances, to other bothersome sensations localizing in muscles, joints, skin, and other parts of the body.3 Learn more about OWS
Symptoms of opioid withdrawal

The peak severity and duration of withdrawal symptoms depend on the half-life of the opioid5,6

  • For shorter-acting opioids, such as Percocet®, OxyContin®, or Vicodin®, withdrawal symptoms peak within 2 to 3 days and can last for 7 to 10 days5,6
  • For longer-acting opioids, such as methadone, withdrawal symptoms peak at 3 to 4 days, but may last for 14 days or more5,6

All trademarks and registered trademarks are the property of their respective owners.

OWS is an obstacle for both opioid-dependent patients and patients with Opioid Use Disorder (OUD)7,8

OWS Is a barrier to opiate discontinuation
  • Successful OWS management can help both physically dependent patients and patients with OUD through opioid withdrawal
  • When treating patients with OUD, LUCEMYRA should only be used in conjunction with a comprehensive management program for the treatment of Opioid Use Disorder


  1. LUCEMYRA™ (lofexidine) [Prescribing Information]. Louisville, KY: US WorldMeds, LLC; 2018.
  2. Weiss RD, Potter JS, Griffith ML, et al. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat. 2014;47(2):140-145.
  3. Shigakova F. Clinical manifestations of the opiate withdrawal syndrome. Int J Biomed. 2015;5(3):151-154.
  4. Vernon MK, Reinders S, Mannix S, et al. Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification. Addict Behav. 2016;60:109-116.
  5. Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003;348(18):1786-1795.
  6. Kleber H. Opioids: detoxification. In: Galanter M, Kleber, HD, eds. Textbook of Substance Abuse Treatment 2nd ed. Washington, DC: American Psychiatric Press;1999:251-269.
  7. Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain–Misconceptions and Mitigation Strategies. N Engl J Med. 2016;374(13):1253-1263.
  8. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13-20.